Nucleos(t)ide Analogues Therapy for Chronic Hepatitis B in Taiwan: Short-Term Versus Long-Term
- 75 Downloads
Chronic hepatitis B (CHB) remains an important health issue in Taiwan. The major candidates for antiviral therapy are HBeAg-positive and -negative CHB patients, and individuals with compensated or decompensated cirrhosis. Lamivudine, adefovir dipivoxil, entecavir, telbivudine, and tenofovir disoproxil fumarate (TDF) are the currently available nucleos(t)ide analogues (NA). Entecavir and TDF are recommended as the first-line agents for long-term use. The therapeutic endpoints recommended by the Asian Pacific Association for the Study of the Liver treatment guidelines have been adopted for clinical practice. Only a small number of patients qualify for short-term NA therapy; the majority of patients need long-term treatment. Current therapeutic endpoints confer off-therapy durability in approximately 50 % of patients. Patients with cirrhosis should receive long-term NA therapy. The use of serum HBsAg level as a guide for cessation of NA therapy requires further investigation.
KeywordsAdefovir dipivoxil Chronic hepatitis B Compensated cirrhosis Consolidation therapy Decompensated cirrhosis Entecavir HBeAg-positive HBeAg-negative HBeAg seroconversion HBsAg HBV DNA Hepatitis B virus Hepatocellular carcinoma Lamivudine Nucleos(t)ide analogue Telbivudine Tenofovir disoproxil fumarate
Conflict of Interest
Cheng-Yuan Peng is a paid board member for Bristol-Myers-Squibb.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 13.•• Tseng TC, Liu CJ, Yang HC, et al.: High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012; 142:1140–1149. Sex, age, HBeAg status, HBV genotype, and levels of ALT and HBV DNA were determinants of hepatocellular carcinoma (HCC) risk. Among HBeAg-negative patients with baseline HBV DNA <2,000 IU/mL, age, ALT level ≥40 U/L, and HBsAg level ≥1,000 IU/mL were determinants of HCC risk. Google Scholar
- 14.•• Tseng TC, Liu CJ, Yang HC, et al.: Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 2013;57:441–450. In genotype B or C infected patients with baseline HBV DNA <2,000 IU/mL, HBsAg level ≥1,000 IU/mL was associated with a higher risk of HBeAg-negative hepatitis, hepatitis flare, and development of cirrhosis during a mean follow-up of 13 years. Google Scholar
- 17.• Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy. J Hepatol. 2012;57:442–450. This is an extensive review on the natural history of chronic hepatitis B after the development of cirrhosis and the recent advances in treatment with oral antiviral agents. Google Scholar
- 18.•• Liaw YF, Kao JH, Piratvisuth T, et al.: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531–561. This is an updated version of the APASL consensus statement on the general management, indications for fibrosis assessment, time to start or stop therapy, choice of first-line therapy, on- and off-therapy monitoring of patients with chronic hepatitis B, and therapy of patients in special circumstances. Google Scholar
- 19.European Association for the Study of the Liver. EASL Clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.Google Scholar
- 21.Marcellin P, Buti M, Gane EJ, et al. Six years of treatment with tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance. Hepatology. 2012;56:374A–5A.CrossRefGoogle Scholar
- 33.• Lee HW, Lee HJ, Hwang JS, et al.: Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology 2010;51:415–421. In 178 HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy for a mean duration of 26 months, 77.5% of patients had sustained virological response at 6 months off therapy. Age ≤40 years and consolidation therapy ≥12 months after HBeAg clearance or seroconversion were independent factors for sustained virological response. Google Scholar
- 35.• Chan HL, Thompson A, Martinot-Peignoux M, et al.: Hepatitis B surface antigen quantification: Why and how to use it in 2011 - A core group report. J Hepatol. 2011; 55:1121–1131. This is a review of the recent advances in the use of serum HBsAg quantitation in the understanding of the natural history and in the assessment of treatment response. Google Scholar
- 39.• Jeng WJ, Sheen IS, Chen YC, et al.: Off therapy durability in chronic hepatitis B e antigen negative patients treated with entecavir. Hepatology 2011;54:1014A-1014A. In 62 HBeAg-negative patients who received entecavir therapy for a mean duration of 735 days and stopped therapy according to the APASL treatment guidelines, 53.2% of patients relapsed at 12 months off therapy. Pre-treatment HBV DNA <2 x 10 5 IU/mL was the only independent predictor of sustained virological response. Google Scholar
- 40.• Jeng WJ, Sheen IS, Chien RN, et al.: Consolidation duration influences the relapse rate post entecavir treatment in HBeAg negative non-cirrhotic patients with chronic hepatitis B. Hepatol Int. 2012;6:105. In 58 non-cirrhotic patients who achieved undetectable HBV DNA levels with entecavir therapy and stopped therapy according to the APASL treatment guidelines, a consolidation period of >64 weeks versus <64 weeks was associated with relapse rates of 25% and 67%, respectively. Google Scholar
- 41.• Chan HL, Wong GL, Chim AM, et al.: Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. Antivir Ther. 2011;16:1249–1257. In 53 HBeAg-negative chronic hepatitis B patients who received lamivudine for a mean duration of 34 months and a mean post-treatment follow-up of 47 months, 17% of patients achieved a sustained response at 12 months off therapy. HBsAg ≤2 log IU/ml and reduction by >1 log from baseline at the end of treatment had sensitivity, specificity, positive and negative predictive values for sustained response of 78%, 96%, 78% and 96%, respectively. Google Scholar
- 43.•• Wong GL, Chan HL, Mak CH, et al.: Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013. doi: 10.1002/hep.26301. Entecavir therapy significantly reduced the 5-year cumulative incidence of hepatic events, development of HCC, and liver-related mortality in cirrhotic patients compared to a historic control group. Cirrhotic patients who failed to achieve undetectable HBV DNA levels during entecavir therapy had a comparable risk of hepatic events as the control group.
- 46.Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut. 2011;60:1109–16.PubMedCrossRefGoogle Scholar
- 47.•• Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al.: Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011;54:91–100. Entecavir showed superior virological and biochemical efficacy to adefovir in patients with HBV-related decompensated cirrhosis. Both agents showed comparable clinical benefits and safety profiles after 48 weeks of therapy. Google Scholar
- 48.• Liaw YF, Sheen IS, Lee CM, et al.: Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011;53:62–72. TDF, emtricitabine/TDF, and entecavir were all well-tolerated in patients with HBV-related decompensated liver disease with improvements in virological, biochemical, and clinical parameters after 48 weeks of therapy. Google Scholar